CORRECTING and REPLACING Hartford Bakery, Inc. Issues Allergy Alert on Undeclared Hazelnuts in Lewis Bake Shop Artisan Style 1/2 Loaf
EVANSVILLE, Ind.--(BUSINESS WIRE)--This updated release corrects the previously reported lot codes included…
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
June 20, 2025 17:00 ET | Source: Inozyme Pharma Inc. BOSTON, June…
Hexagon launches AEON, a humanoid built for industry
Hexagon leverages industry-leading expertise in measurement technologies, AI and autonomous systems to…
Draganfly Announces Additional Exercise Of Over-Allotment Option
Saskatoon, SK., June 06, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO)…
CITGO Sale Hearing Date Rescheduled to August 18, 2025
PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) (“Gold Reserve” or…
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 05, 2025 16:58 ET | Source: Boundless Bio, Inc. SAN DIEGO,…
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
June 05, 2025 16:31 ET | Source: ImPact Biotech – Previously inoperable…
OHI Group S.A. Announces Consent Solicitation Relating to its U.S.$400,000,000 13.000% Senior Secured Amortizing Notes due 2029 Regulation S Notes: CUSIP L7S61M AB5, ISIN USL7S61MAB59 Rule 144A Notes: CUSIP 67712M AB5, ISIN US67712MAB54 (the “Notes”)
Executive Summary — As previously announced, OHI Group S.A. (the "Issuer") is preparing…
HOTEL101 PROGRESSES TOWARDS NASDAQ LISTING
U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE SINGAPORE, June 2, 2025…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…